Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma.

[1]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[2]  M. Tsai,et al.  Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. , 1997, Cancer research.

[3]  M. Gleave,et al.  A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. , 1997, Cancer research.

[4]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[5]  A. Robles,et al.  Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[7]  H. Klocker,et al.  Regulation of prostatic growth and function by peptide growth factors , 1996, The Prostate.

[8]  M. Gleave,et al.  Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  L. Hengst,et al.  Translational Control of p27Kip1 Accumulation During the Cell Cycle , 1996, Science.

[10]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[11]  S. Elledge,et al.  Cdk inhibitors: on the threshold of checkpoints and development. , 1994, Current opinion in cell biology.

[12]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[13]  W. Grizzle,et al.  Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. , 1994, Journal of the National Cancer Institute.

[14]  H. Wiley,et al.  Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. , 1993, The Journal of clinical endocrinology and metabolism.

[15]  E. Boven.  The Nude Mouse in Oncology Research , 1991 .

[16]  N. Kyprianou,et al.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. , 1990, Cancer research.

[17]  N. Kyprianou,et al.  Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death , 1989 .

[18]  G. Hommel.  A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[19]  P. Briand,et al.  The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. , 1975, Cancer research.

[20]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[21]  M. J. Ravitz,et al.  Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. , 1997, Advances in cancer research.

[22]  M. Gleave,et al.  Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. , 1996, The Journal of urology.

[23]  James M. Roberts,et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.